India · Delayed Price · Currency is INR Krsnaa Diagnostics Earnings Call Transcripts
Fiscal Year 2026
-
FY 2026 saw revenue of INR 7,728 million, EBITDA margin of 28%, and PAT of INR 1,014 million, with strong growth in retail and major PPP expansion in Rajasthan. Receivables improved, CapEx of INR 5,000 million planned, and EBITDA margins are expected to be maintained.
-
Q3 FY26 saw modest 4% revenue growth, strong cash recovery, and resilient margins despite seasonality and expansion costs. Retail revenue surged 8x year-over-year, and the Rajasthan project is set to drive significant growth by FY27.
-
Q2 FY26 saw 11% revenue growth and 18% EBITDA growth, with margins expanding to 29%. Retail business surged 60% quarter-on-quarter and is expected to reach 15-20% of revenue next year. Major PPP projects and retail expansion are set to drive future growth.
-
Q1 FY 2026 saw 13% revenue growth, 19% EBITDA growth, and 15% PAT growth, with retail revenue rising to 6% of total. The Rajasthan PPP contract expands scale, with full rollout in 6-9 months and material revenues from FY 2027. Margins and working capital remain strong.
Fiscal Year 2025
-
Revenue grew 16% year-on-year to INR 7,172 million in FY 2025, with EBITDA up 34% and net profit up 37%. Retail diagnostics expanded rapidly, and margins improved to 27%. Receivable days are targeted to reduce, and asset-light expansion will keep CapEx low.
-
Revenue grew 10% YoY in Q3 and 17% for nine months, with net profit up 50% YoY in Q3. Operational delays and project ramp-ups impacted quarterly results, but management expects strong growth in Q4 and FY26, driven by new center activations and retail expansion.
-
Q2 FY2025 saw 20% revenue growth and 87% PAT growth, driven by new project wins, operational efficiencies, and strategic investments in oncology and cardiac care. The company remains net debt-free, expects receivable days to normalize, and maintains guidance for 25% revenue growth and stable margins.
-
Q1 FY25 saw 22% revenue growth and 39% EBITDA growth, with strong expansion in radiology and pathology services. The company remains net debt-free, is executing multi-year PPP contracts, and is accelerating retail and digital initiatives for future growth.